In an article published on AJMC.com, IVI'sJennifer Bright discusses how IVI makes incorporating patients' perspectives a priority in developing open-source, transparent value models. Read the full article here.
Los Angeles, CA – November 15, 2018 – The Innovation and Value Initiative (IVI) – a nonprofit dedicated to advancing the science and improving the practice of value assessment in healthcare – today released qualitative research evaluating what factors most impact the value of treatment to metastatic non-small cell lung cancer patients. According to the [...]
IVI has released the results to their non-small cell lung cancer patient qualitative research, which was used in the development of the structure of upcoming OSVP designed to evaluate lung cancer therapy sequences. According to the research, which was conducted in collaboration with LUNGevity, patients reported valuing treatments that would help increase overall or progression [...]
In an article published on AJMC.com, IVI'sJennifer Bright and Mark Linthicum argue value assessment stakeholders need to have transparent discussions about value assessment and understand what value means from other points of view. Read the full article here.
IVI's Jennifer Bright participated in a panel of discussion at the recent Value-Based Summit, organized by Xtelligent media. Bright's panel, "Healthcare Quality Measurement," examined how healthcare stakeholders are looking at insights derived from measurement initiatives to support value-based care. Read more here.
While it makes sense for value assessment to be woven into healthcare decision making, relying on a single method to measure value and using this metric to restrict treatment access is shortsighted. IVI's Jennifer Bright and Mark Linthicum address this concern in a recent article for the American Journal of Managed Care (AJMC). Read the [...]
There isn't an easy answer to assessing value in healthcare, but IVI is working to tackle the problems through considerable research and experimentation by developing an open-source value platform that considers no only clinical factors, but patient perspectives as well. In a recent interview with PatientEngagementHIT.com, IVI's Jennifer Bright (Executive Director) and Mark Linthicum (Director [...]
CVS Health's pharmacy benefit management (PBM) division, CVS Caremark, recently announced their decision to rely exclusively on the analyses of the Institute for Clinical and Economic (ICER) in a new drug management program. IVI's Director of Scientific Communications, Mark Linthicum, responds to this story in MedCity stating, "The neat 'answer' regarding the value of treatment [...]
In a post on the IVI-sponsored Health Affairs featured blog series Drugs and Medical Innovation, Daniel Blumenthal, Samuel Nussbaum (IVI Strategic Advisory Panel Chair), Mark Linthicum (IVI Director of Scientific Communications), and Neil Weissman (IVI Strategic Advisory Panel member) explore how outcomes-based pricing agreements (OBAs) could be utilized for medical devices used to treat cardiovascular [...]
Over the last decade, insurers have increasingly used step therapy or “fail-first,” policies as a strategy to contain pharmaceutical costs. Step therapy requires patients to begin treatment for a medical condition on a typically less expensive drug, and only progress to more costly second-line drugs when the first-line therapy becomes ineffective or inappropriate. Step therapy [...]
